Literature DB >> 11748732

Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET.

G Berding1, P Odin, D J Brooks, G Nikkhah, C Matthies, T Peschel, M Shing, H Kolbe, J van Den Hoff, H Fricke, R Dengler, M Samii, W H Knapp.   

Abstract

Studies of resting regional cerebral glucose consumption (rCMRGlc) in nondemented patients with Parkinson's disease (PD) have produced conflicting results, reporting both reduced and normal metabolism in advanced disease and reduced or normal metabolism after dopaminergic therapy. To investigate these issues, [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) was performed in 11 nondemented PD patients with advanced disease and 10 age-matched controls. PD patients were studied after withdrawal of all dopaminergic medication to produce a practically defined off condition, and a second time 1 hour after levodopa, resulting in a clinical on state. Dynamic PET scans and simultaneous arterialised venous blood samples of [(18)F] activity were obtained. A graphical approach was used to generate parametric images of rCMRGlc and statistical parametric mapping to localise significant metabolic changes in PD. Compared with controls, global rCMRGlc was reduced in the on but not in the off condition in PD. In both states, significant regional reductions of glucose uptake were found in the parietal, frontal, temporal cortex, and caudate nucleus. Reductions correlated with the severity of disability in frontal and temporal cortex. Direct comparison between on and off conditions revealed relatively greater reductions of uptake in the ventral/orbital frontal cortex and the thalamus during on. Results suggest that cortical and caudate hypometabolism are common in advanced PD and that caution is mandatory if [(18)F]FDG PET is being used to differentiate advanced PD from dementia and progressive supranuclear palsy where similar reductions are seen. Furthermore, in PD, administration of levodopa is associated with further hypometabolism in orbitofrontal cortex; an area known to be relevant for reversal learning where performance is typically impaired after dopaminergic treatment. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748732     DOI: 10.1002/mds.1212

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  33 in total

1.  Subthalamic nucleus stimulation affects limbic and associative circuits: a PET study.

Authors:  Florence Le Jeune; Julie Péron; Didier Grandjean; Sophie Drapier; Claire Haegelen; Etienne Garin; Bruno Millet; Marc Vérin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-28       Impact factor: 9.236

2.  Primary motor cortex of the parkinsonian monkey: differential effects on the spontaneous activity of pyramidal tract-type neurons.

Authors:  Benjamin Pasquereau; Robert S Turner
Journal:  Cereb Cortex       Date:  2010-11-02       Impact factor: 5.357

3.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

Authors:  Andrea Varrone; Susanne Asenbaum; Thierry Vander Borght; Jan Booij; Flavio Nobili; Kjell Någren; Jacques Darcourt; Ozlem L Kapucu; Klaus Tatsch; Peter Bartenstein; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

Review 4.  Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.

Authors:  Shigeki Hirano; Thomas Eckert; Toni Flanagan; David Eidelberg
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

5.  Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease.

Authors:  Tracy R Melzer; Richard Watts; Michael R MacAskill; John F Pearson; Sina Rüeger; Toni L Pitcher; Leslie Livingston; Charlotte Graham; Ross Keenan; Ajit Shankaranarayanan; David C Alsop; John C Dalrymple-Alford; Tim J Anderson
Journal:  Brain       Date:  2011-02-09       Impact factor: 13.501

Review 6.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

7.  PET studies of cerebral metabolism in Parkinson disease.

Authors:  William J Powers
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

Review 8.  Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.

Authors:  D Allan Butterfield; Miranda L Bader Lange
Journal:  J Neurochem       Date:  2009-09-23       Impact factor: 5.372

9.  Regional, kinetic [(18)F]FDG PET imaging of a unilateral Parkinsonian animal model.

Authors:  Matthew D Silva; Charles Glaus; Jacob Y Hesterman; Jack Hoppin; Geraldine Hill Della Puppa; Timothy Kazules; Kelly M Orcutt; Mary Germino; David Immke; Silke Miller
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.